Amgen Mexico – Elvin Penn, Executive Director & General Manager
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact details
Ave. Vasco de Quiroga 3000 piso 4
Col. Santa Fe, Del. Alvaro Obregón
CP 01210 México DF
MEXICO
Tel. +52 (55) 4424 4600
www.amgen.mx
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…
Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare…
During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando Cruz, qualified as “reasonably good” considering the impacts…
The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout…
While Mexico struggles with its COVID-19 vaccination campaign, residents of the country’s northern states have begun flying to the United States in search of a shot. Fearful of “fake vaccines”…
Last Wednesday, the lower chamber of the Mexican Congress approved a bill that would legalise recreational marijuana. With a population of nearly 130 million people, Mexico would join Canada and…
The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by Western companies, and AMLO’s call for…
See our Cookie Privacy Policy Here
